INTRODUCTION {#s1}
============

Despite decreasing incidence and mortality, gastric cancer remains the fifth most common cancer and the third most common cause of cancer-related death worldwide \[[@R1]\]. A number of environmental factors are correlated with gastric cancer development \[[@R2]--[@R5]\]. Additionally, a family history of cancer, especially gastric cancer, is associated with increased risk of developing the disease \[[@R6], [@R7]\]. It is estimated that approximately 13.5% to 46.4% of gastric cancer patients have a family history of cancer \[[@R8]--[@R10]\]. Recently, longer overall survival has been reported in other cancer patients with a family history of cancer \[[@R11], [@R12]\]. Although some studies have reported the clinicopathological features and prognosis of gastric cancer patients with a family history of cancer, these results have been inconsistent \[[@R8], [@R9], [@R13], [@R14]\]. Therefore, the effect of family history of cancer on survival in gastric cancer patients is still unclear. To clarify this question, we conducted this study to evaluate the correlation between family history of cancer and clinicopathologic characteristics and overall survival of gastric cancer patients.

RESULTS {#s2}
=======

Clinicopathological characteristics {#s2_1}
-----------------------------------

Patients included 1263 males and 542 females (2.3:1) with a mean age of 58 years. There were 339 (18.8%) early gastric cancers and 1466 (81.2%) advanced gastric cancers. Differentiated tumors were observed in 471 (26.1%) patients, and undifferentiated in 1334 (73.9%) patients. 339 (18.8%) were type 0, 9 (0.5%) type I, 502 (27.8%) type II, 879 (48.7%) type III, 76 (4.2%) type IV. Of 1805 patients, 577 (32.0%) had tumors located in the upper third, 298 (16.5%) had tumors in the middle third, 821 (45.5%) had tumors in the lower third of the stomach, and 109 (6.0%) had tumors occupying two-thirds or more of stomach. Lymph node metastasis was observed in 1122 patients (62.2%). The distribution of pathological stage was as follows: 279 (15.5%) patients had stage IA tumors, 216 (12.0%) IB, 186 (10.3%) IIA, 244 (13.5%) IIB, 230 (12.7%) IIIA, 291 (16.1%) IIIB, and 359 (19.9%) IIIC. Patients demographics are listed in Table [1](#T1){ref-type="table"}.

###### Patient cohort

                             *n* =1805   100%
  -------------------------- ----------- ------
  Sex                                    
   Male                      1263        70.0
   Female                    542         30.0
  Age (yr)                               
   \<60                      997         55.2
   ≥60                       808         44.8
  Tumor size (cm)                        
   \<5                       902         61.6
   ≥5                        562         38.4
  Histological type                      
   Differentiated            471         26.1
   Undifferentiated          1334        73.9
  Tumor location                         
   Upper third               577         32.0
   Middle third              298         16.5
   Lower third               821         45.5
   Two-third or more         109         6.0
  Borrmann type                          
   0                         339         18.8
   I                         9           0.5
   II                        502         27.8
   III                       879         48.7
   IV                        76          4.2
  Vascular tumor emboli                  
   Yes                       620         34.3
   No                        1185        65.7
  Nervous invasion                       
   Yes                       657         36.4
   No                        1148        63.6
  Pathological stage                     
   IA                        279         15.5
   IB                        216         12.0
   IIA                       186         10.3
   IIB                       244         13.5
   IIIA                      230         12.7
   IIIB                      291         16.1
   IIIC                      359         19.9
  Family history of cancer               
   Positive                  382         21.2
   Negative                  1423        78.8
  Smoking                                
   Yes                       193         10.7
   No                        1612        89.3
  Drinking                               
   Yes                       127         7.0
   No                        1678        93.0
  P21 expression                         
   Positive                  1134        62.8
   Negative                  671         37.2
   P53 expression                        
   Positive                  1319        73.1
   Negative                  486         26.9
  c-myc expression                       
   Positive                  1138        63.0
   Negative                  667         37.0
  EGFR expression                        
   Positive                  697         38.6
   Negative                  1108        61.4
  Neu/Her-2                              
   Positive                  43          2.4
  Negative                   1762        97.6

Immunohistochemical characteristics {#s2_2}
-----------------------------------

The expression of p21, p53, c-myc, EGFR and Neu/Her-2 was examined by immunohistochemical staining. The location of staining was predominantly in the cell nucleus for p21 and p53, cell cytoplasm for c-myc, cell cytoplasm or membrane for EGFR, and membrane for Neu/Her-2. The positive expression rates of p21, p53, c-myc, EGFR, and Neu/Her-2 were 62.8%, 73.1%, 63.0%, 38.6%, and 2.4%, respectively.

Family history of cancer {#s2_3}
------------------------

Of 1805 patients, 382 (21.2%) had at least one relative with any type of cancer. By cancer type, gastric cancer was the most common and occurred in 190 patients (10.5%), while 192 patients (10.6%) had a family history of other cancers. 348 (19.3%) patients had a family history in first-degree relatives, and 34 (1.9%) in second-degree relatives. In the patients with a family history of gastric cancer, 169 (9.4%) had a family history in first-degree relatives and 21 (1.2%) in second-degree relatives. Data is shown in Table [2](#T2){ref-type="table"}.

###### Family histories of cancer in gastric cancer patients

  Family history                             No. of patients (1805)   \%
  ------------------------------------------ ------------------------ ------
  Cancer                                                              
   Yes                                       382                      21.2
   No                                        1423                     78.8
   Relatives                                                          
    First degree                             348                      19.3
    Second degree                            34                       1.9
   No. of relatives with cancer                                       
    1                                        258                      14.3
    ≥2                                       124                      6.9
   Cancer type                                                        
    Gastric cancer                           190                      10.5
    All other cancers                        192                      10.6
  Gastric cancer                                                      
   Yes                                       190                      10.5
   No                                        1615                     89.5
   Relatives                                                          
    First degree                             169                      9.4
    Second degree                            21                       1.2
   No. of relatives with gastric cancer                               
    1                                        113                      6.3
    ≥2                                       77                       4.3
  All other cancers without gastric cancer                            
   Yes                                       192                      10.6
   No                                        1613                     89.4
   Relatives                                                          
    First degree                             179                      9.9
    Second degree                            13                       0.7
   No. of relatives with cancer                                       
    1                                        145                      8.0
    ≥2                                       47                       2.6

Demographic and clinicopathologic features of PFH {#s2_4}
-------------------------------------------------

Demographically, patients with a positive family history of cancer were younger than patients without positive family history of cancer. There was no difference in gender distribution between the two groups. In patients with a positive family history of cancer, the proportion of smoking and alcohol use was higher than in patients without family history. Clinicopathologically, significant differences were observed in degree of differentiation, tumor location, tumor size, and p21 expression between the two groups. Patients with a positive family history of cancer had a higher rate of undifferentiated tumors and lower 1/3 tumors, smaller tumors, and a lower rate of p21 expression than in those without a positive family history. Data were shown in Table [3](#T3){ref-type="table"}.

###### Comparison of the clinicopathological characteristics of patients with positive family history of cancer (PFH) and negative family history of cancer (NFH)

  Variables               PFH *n*= 382   NFH *n*= 1423   *P*
  ----------------------- -------------- --------------- ---------
  Gender                                                 0.297
   Male                   259            1004            
   Female                 123            413             
  Age (yr)                                               0.0003
   \<60                   242            755             
   ≥60                    140            668             
  Tumor size (cm)                                        0.007
   \<5                    267            889             
   ≥5                     115            534             
  Histological type                                      0.002
   Differentiated         76             395             
   Undifferentiated       306            1028            
  Tumor location                                         0.021
   Upper third            97             480             
   Middle third           67             231             
   Lower third            192            629             
   Two-third or more      26             83              
  Borrmann type                                          0.088
   0                      88             251             
   I                      3              6               
   II                     93             409             
   III                    180            699             
   IV                     18             58              
  Vascular tumor emboli                                  0.483
   Yes                    137            483             
   No                     245            940             
  Nervous invasion                                       0.152
   Yes                    151            506             
   No                     231            917             
  Pathological stage                                     0.207
   IA                     73             206             
   IB                     47             169             
   IIA                    37             149             
   IIB                    51             193             
   IIIA                   47             183             
   IIIB                   48             243             
   IIIC                   79             280             
  Smoking                                                \<0.001
   Yes                    70             123             
   No                     312            1300            
  Drinking                                               0.001
   Yes                    41             86              
   No                     341            1337            
  P21 expression                                         0.012
   Positive               219            915             
   Negative               163            508             
  P53 expression                                         0.985
   Positive               279            1040            
   Negative               103            383             
  c-myc expression                                       0.158
   Positive               229            909             
   Negative               153            514             
  EGFR expression                                        0.066
   Positive               132            565             
   Negative               250            858             
  Neu/Her-2                                              0.054
   Positive               4              39              
   Negative               378            1384            

Univariate analysis {#s2_5}
-------------------

The overall 5-year survival rate was 53% for all patients. The 5-year survival rates of PFH and NFH groups were 60% and 52%, and the difference was statistically significant (Figure [1](#F1){ref-type="fig"}). Additionally, significant prognostic factors included age, differentiation, vascular tumor emboli, nervous invasion, tumor location, tumor size, Borrmann type, TNM stage, family history of gastric cancer, family history of other cancers, p21 overexpression, Neu/Her-2 overexpression, and EGFR overexpression (Table [4](#T4){ref-type="table"}). In the PFH group, vascular tumor emboli, nervous invasion, tumor location, tumor size, Borrmann type, TNM stage, p21 overexpression, and c-myc overexpression were significant prognostic factors for survival (Table [5](#T5){ref-type="table"}). In the NFH group, age, differentiation, venous tumor emboli, nervous invasion, tumor location, tumor size, Borrmann type, TNM stage, p21 overexpression, Neu/Her-2 overexpression, and EGFR overexpression were significantly correlated with prognosis (Table [6](#T6){ref-type="table"}).

![Kaplan-Meier survival curves by family history of cancer\
There were significant differences between PFH and NFH.](oncotarget-07-37305-g001){#F1}

###### Univariate analysis of all patients by Kaplan-meier method

  Variable                           *n*    5-Year survival rate (%)   *P* value
  ---------------------------------- ------ -------------------------- -----------
  Sex                                                                  0.659
   Male                              1263   52.4                       
   Female                            542    55.4                       
  Age (yr)                                                             \<0.001
   \<60                              997    58.9                       
   ≥60                               808    46.4                       
  Tumor size (cm)                                                      \<0.001
   \<5                               1156   62.3                       
   ≥5                                649    37.4                       
  Histological type                                                    \<0.001
   Differentiated                    471    62.0                       
   Undifferentiated                  1334   50.3                       
  Tumor location                                                       \<0.001
   Upper third                       577    41.2                       
   Middle third                      298    51.2                       
   Lower third                       821    66.1                       
   Two-third or more                 109    26.2                       
  Borrmann type                                                        \<0.001
   0                                 339    91.3                       
   I                                 9      40.3                       
   II                                502    51.1                       
   III                               879    42.8                       
   IV                                76     21.1                       
  Vascular tumor emboli                                                \<0.001
   Yes                               620    31.4                       
   No                                1185   64.8                       
  Nervous invasion                                                     \<0.001
   Yes                               657    33.4                       
   No                                1148   64.7                       
  Pathological stage                                                   \<0.001
  IA                                 279    93.7                       
  IB                                 216    88.6                       
  IIA                                186    66.8                       
  IIB                                244    56.8                       
  IIIA                               230    47.2                       
  IIIB                               291    30.4                       
  IIIC                               359    13.0                       
  Smoking                                                              0.061
   Yes                               193    52.5                       
   No                                1612   60.3                       
  Drinking                                                             0.240
   Yes                               127    57.9                       
   No                                1678   53.0                       
  Family history of cancer                                             0.001
   Positive                          382    59.8                       
   Negative                          1423   51.6                       
  Family history of gastric cancer                                     0.031
   Positive                          190    54.2                       
   Negative                          1615   43.0                       
  Family history of other cancers                                      0.038
   Positive                          192    54.2                       
   Negative                          1613   43.0                       
  P21 expression                                                       0.002
   Positive                          1134   50.5                       
   Negative                          671    58.0                       
  P53 expression                                                       0.606
   Positive                          1319   54.0                       
   Negative                          486    51.5                       
  c-myc expression                                                     0.333
   Positive                          1138   52.4                       
   Negative                          667    54.8                       
  EGFR expression                                                      0.006
   Positive                          697    48.3                       
   Negative                          1108   56.3                       
  Neu/Her-2                                                            0.019
   Positive                          43     30.2                       
   Negative                          1762   53.8                       

###### Kaplan-Meier univariate analysis of patients with PFH

  Variable                *n*   5-Year survival rate (%)   *P* value
  ----------------------- ----- -------------------------- -----------
  Sex                                                      0.540
   Male                   259   57.1                       
   Female                 123   65.8                       
  Age (yr)                                                 0.380
   \<60                   242   60.7                       
   ≥60                    140   58.9                       
  Tumor size (cm)                                          \<0.001
   \<5                    267   67.9                       
   ≥5                     115   41.3                       
  Histological type                                        0.160
   Differentiated         76    65.9                       
   Undifferentiated       306   57.9                       
  Tumor location                                           \<0.001
   Upper third            97    50.3                       
   Middle third           67    61.9                       
   Lower third            192   68.5                       
   Two-third or more      26    23.1                       
  Borrmann type                                            \<0.001
   0                      88    91.4                       
   I                      3     0.0                        
   II                     93    63.9                       
   III                    180   44.7                       
   IV                     18    33.3                       
  Vascular tumor emboli                                    \<0.001
   Yes                    137   37.6                       
   No                     245   71.5                       
  Nervous invasion                                         \<0.001
   Yes                    151   41.9                       
   No                     231   71.2                       
  Pathological stage                                       \<0.001
  IA                      73    93.8                       
  IB                      47    88.8                       
  IIA                     37    73.3                       
  IIB                     51    60.8                       
  IIIA                    47    58.7                       
  IIIB                    48    41.7                       
  IIIC                    79    13.8                       
  Smoking                                                  0.833
   Yes                    70    57.3                       
   No                     312   60.1                       
  Drinking                                                 0.819
   Yes                    41    58.5                       
   No                     341   59.9                       
  P21 expression                                           0.041
   Positive               219   54.9                       
   Negative               163   66.8                       
  P53 expression                                           0.535
   Positive               279   61.1                       
   Negative               103   55.8                       
  c-myc expression                                         0.017
   Positive               229   54.8                       
   Negative               153   66.8                       
  EGFR expression                                          0.196
   Positive               132   53.0                       
   Negative               250   63.3                       
  Neu/Her-2                                                0.545
   Positive               4     50.0                       
   Negative               378   60.1                       

###### Kaplan-Meier univariate analysis of patients with NFH

  Variable                *n*    5-Year survival rate (%)   *P* value
  ----------------------- ------ -------------------------- -----------
  Sex                                                       0.939
   Male                   1004   51.2                       
   Female                 419    52.4                       
  Age (yr)                                                  \<0.001
   \<60                   755    58.3                       
   ≥60                    668    43.8                       
  Tumor size (cm)                                           \<0.001
   \<5                    889    60.5                       
   ≥5                     534    36.5                       
  Histological type                                         \<0.001
   Differentiated         395    60.9                       
   Undifferentiated       1028   47.8                       
  Tumor location                                            \<0.001
   Upper third            480    39.2                       
   Middle third           231    47.8                       
   Lower third            629    65.3                       
   Two-third or more      83     26.7                       
  Borrmann type                                             \<0.001
   0                      251    90.9                       
   I                      6      50.0                       
   II                     409    48.0                       
   III                    699    42.1                       
   IV                     58     17.2                       
  Vascular tumor emboli                                     \<0.001
   Yes                    483    29.5                       
   No                     940    62.7                       
  Nervous invasion                                          \<0.001
   Yes                    506    30.6                       
   No                     917    62.9                       
  Pathological stage                                        \<0.001
  IA                      206    93.4                       
  IB                      169    88.6                       
  IIA                     149    65.2                       
  IIB                     193    55.7                       
  IIIA                    183    43.3                       
  IIIB                    243    28.2                       
  IIIC                    280    12.8                       
  Smoking                                                   0.050
   Yes                    123    60.9                       
   No                     1300   50.6                       
  Drinking                                                  0.334
   Yes                    86     57.1                       
   No                     1337   51.1                       
  P21 expression                                            0.031
   Positive               915    49.4                       
   Negative               508    55.4                       
  P53 expression                                            0.781
   Positive               1040   52.0                       
   Negative               383    50.2                       
  c-myc expression                                          0.781
   Positive               909    51.8                       
   Negative               514    51.1                       
  EGFR expression                                           0.023
   Positive               565    47.4                       
   Negative               858    54.3                       
  Neu/Her-2                                                 0.037
   Positive               39     28.2                       
   Negative               1384   52.2                       

Multivariate analysis {#s2_6}
---------------------

Multivariate analysis showed that family history of cancer, age, tumor differentiation, vascular tumor emboli, Borrmann type, tumor size, TNM stage, and p21 overexpression were independent prognostic factors for all patients (Table [7](#T7){ref-type="table"}). In the PFH group, TNM stage and c-myc overexpression were significant prognostic factors (Table [8](#T8){ref-type="table"}). In the NFH group, age, differentiation, vascular tumor emboli, and TNM stage were independent prognostic factors (Table [9](#T9){ref-type="table"}).

###### Multivariate analysis of patients by Cox model

  Variable                                                              *P* value   RR      95% CI
  --------------------------------------------------------------------- ----------- ------- -------------
  Age                                                                   \<0.001     1.327   1.170-1.505
  Histological type                                                     0.007       1.234   1.060-1.437
  Vascular tumor emboli                                                 0.005       1.225   1.065-1.409
  Nervous invasion                                                      0.149       1.108   0.964-1.273
  Tumor location                                                        0.081       0.944   0.885-1.007
  Borrmann type                                                         0.041       1.093   1.004-1.191
  Tumor size                                                            0.035       1.149   1.010-1.308
  Pathological stage                                                    \<0.001     1.464   1.400-1.532
  Family history of cancer[\*](#tfn_001){ref-type="table-fn"}           0.033       0.836   0.708-0.986
  Family history of gastric cancer[\*](#tfn_001){ref-type="table-fn"}   0.309       0.891   0.714-1.113
  Family history of other cancers[\*](#tfn_001){ref-type="table-fn"}    0.073       0.817   0.655-1.019
  P21                                                                   0.045       1.146   1.003-1.309
  EGFR                                                                  0.183       1.091   0.960-1.240
  Neu/Her-2                                                             0.173       1.287   0.895-1.851

Only one parameter can be put into Cox proportional hazards model very time.

###### Multivariate analysis of patients with PFH

  Variable                *P* value   RR      95% CI
  ----------------------- ----------- ------- -------------
  Vascular tumor emboli   0.109       1.312   0.942-1.830
  Nervous invasion        0.506       1.120   0.802-1.562
  Tumor location          0.404       0.934   0.796-1.096
  Tumor size              0.165       1.253   0.911-1.724
  Borrmann type           0.097       1.184   0.970-1.445
  Pathological stage      \<0.001     1.452   1.305-1.617
  P21                     0.094       1.307   0.955-1.787
  c-myc                   0.028       1.424   1.039-1.953

###### Multivariate analysis of patients with NFH

  Variable                *P* value   RR      95% CI
  ----------------------- ----------- ------- -------------
  Age                     \<0.001     1.393   1.212-1.601
  Histological type       0.005       1.270   1.077-1.499
  Vascular tumor emboli   0.019       1.203   1.030-1.405
  Nervous invasion        0.182       1.110   0.952-1.293
  Tumor location          0.115       0.944   0.880-1.014
  Tumor size              0.085       1.133   0.983-1.305
  Borrmann type           0.140       1.074   0.977-1.180
  Pathological stage      \<0.001     1.469   1.397-1.544
  P21                     0.171       1.108   0.957-1.284
  EGFR                    0.140       1.112   0.966-1.280
  Neu/Her-2               0.188       1.287   0.884-1.876

Comparison of survival according to stage between PFH and NFH groups {#s2_7}
--------------------------------------------------------------------

According to the AJCC/TNM staging, gastric cancer patients were divided into stage I, stage II, and stage III. According to family history of cancer, each stage was divided into PFH and NFH groups. There was a statistically significant difference in overall survival between the PFH and NFH groups for patients with stage III tumors (*P* \<0.05, Figure [2](#F2){ref-type="fig"}).

![Comparison of survival according to tumor stage\
There were significant differences between PFH and NFH according to stage III.](oncotarget-07-37305-g002){#F2}

DISCUSSION {#s3}
==========

Familial aggregation is quite common in all kinds of cancers. In this study, 21.2% of gastric patients had a positive family history of cancer. This is similar to that reported in previous studies \[[@R8]--[@R10]\]. The reason for familial aggregation is unclear. It is possible that environmental factors or genetic factors contribute to this. Some studies have shown that environmental factors such as diet or socioeconomic status were significantly associated with risk of family gastric cancer \[[@R15], [@R16]\]. Additionally, Some studies have reported that microsatellite instability (MSI) was associated with family history of gastric cancer \[[@R17], [@R18]\]. Lee et al. reported that p53 overexpression may increase familial aggregation of gastric cancer \[[@R8]\]. In the current study, we examined expression of some genes, and we found that p21 expression by tumor cells correlated with family history of gastric cancer. Further study is needed to elucidate the mechanism.

In this study, we found that gastric cancer patients with family history of cancer had different clinicopathological features compared to those without a family history of cancer. Our results showed that patients with a family history of cancer were younger than patients without family history of cancer. However, this result was inconsistent with that reported by a Korean study \[[@R9]\], which found that there was no significant difference in mean ages between familiar gastric cancer and sporadic cancer. It is possible that difference is due to the bias of self-reported family history. Another two recent studies have confirmed our results \[[@R19], [@R20]\]. Additionally, we found that patients with positive family history of cancer had a higher rate of lower 1/3 tumors. Inoue et al \[[@R21]\] also reported that tumors were more frequently located in the lower and middle part of the stomach in gastric cancer patients with a positive family history. In all, the differences of clinicopathological features and some genes expression between two groups indicated that gastric cancer with positive family history may represent a distinct disease.

Although some studies have reported the effects of a positive family history on the survival of patients with gastric cancer, the results were controversial \[[@R8], [@R9], [@R13], [@R14]\]. These inconsistencies might be due to the adjustment range of confounding variables. Additionally, it might be explained by low statistical power as a result of small-scale sample. In our study, family history of cancer was consistently associated with prognosis in both univariate and multivariate analyses after adjustment for prognostic variables. It is not clear why a family history of cancer increase survival. It is possible that a family history of cancer may heighten awareness of gastric cancer in family members, leading to earlier diagnosis and better prognosis. We found that patients with a positive family history were more likely to have smaller tumor size. However, the current study could not confirm this hypothesis as a result of no information about previous screening. Some studies have shown that patients with a family history of cancer are more likely to undergo cervical cancer and prostate cancer screening \[[@R22], [@R23]\]. Additionally, health behaviour may also have contributed to the better survival of patients with family history of cancer. Patients with a family history of cancer more likely to have good behavioural habits, like quitting smoking, or healthy dietary habits \[[@R24], [@R25]\]. Given the fact that smoking and drinking habits are associated with poor prognosis in gastric cancer, a reduced incidence of unhealthy behaviour may partly account for improved prognosis. Han et al. reported that proportions of current smokers or drinkers were significantly lower in patients with a family history of cancer\[[@R9]\]. In contrast, we found that proportions of smokers or drinkers were significantly higher in patients with family history, and smoking or drinking did not affect the survival of gastric cancer patients. Therefore, the effect of health behaviour on prognosis needs further investigation. Finally, genetics may also account for the survival differences of gastric cancer patients with a family history. Microsatellite instability (MSI) is detected frequently in gastric cancer. It has been reported that MSI is associated with a family history of gastric cancer and better overall prognosis \[[@R17], [@R18], [@R26]\]. In this study, expressions of p21, p53, c-myc, EGFR and Neu/Her-2 were examined by immunohistochemical staining. We found that rate of p21 expression was lower in patients with family history. In addition, multivariate analysis showed that p21 expression was an adverse independent prognostic factor for gastric cancer. These results indicated that low expression of p21 contributed to the good prognosis of gastric cancer patients with family history of cancer. However, the exact mechanism is unclear, and further study is needed.

A limitation of our study is that it has relied on self-reported family history, and the family history information was not confirmed pathologically. However, we confirmed the family history by asking patients\' relatives in order to reduce the probability of under-reports or over-reports. Secondly, we did not investigate genetic mutations for MSI or CDH1.

In conclusion, our study showed that the prognosis of gastric cancer patients with a family history of cancer was better than that of patients without a family history. Given the association of p21 expression and family history of cancer, this result may facilitate further development of agents targeting p21 expression and clinical trials evaluating the role of these agent in gastric cancer patients with a family history of cancer.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

From 2000 to 2008, 1805 patients with histologically confirmed primary gastric adenocarcinoma underwent curative gastrectomy at the Department of Gastric Cancer and Soft Tissue Sarcoma Surgery, Fudan University Shanghai Cancer Center. Exclusion criteria for this study were as follows: (1) surgery status unknown; (2) vital status unknown; (3) uncompleted pathological data. Data were retrieved from operative and pathological reports. Follow-up data were obtained by phone, outpatient visits and our clinical database. Written informed consent was obtained from all patients, and this study was approved by the Ethical Committee of Fudan University Shanghai Cancer Center. Staging was done according to the American Joint Committee on Cancer (AJCC) TNM Staging Classification for Carcinoma of the Stomach (Seventh Edition, 2010). Gastrectomy was performed in accordance with the Japanese Classification of Gastric Carcinoma.

Immunohistochemical staining {#s4_2}
----------------------------

The expression of p21, p53, c-myc, EGFR, and Neu/Her-2 in primary lesions was detected by immunohistochemical staining. All primary antibodies and mouse monoclonal antibodies were purchased from Dako (Hamburg, Germany). The detailed sources, concentrations of antibody and positive site were as follows: anti-p21 (clone SX118), 1:50 dilution, nucleus; anti-p53 (clone DO-7), 1:100 dilution, nucleus; anti-c-myc (clone 9E10), 1:100 dilution, cytoplasm; anti-EGFR (clone E30), 1:50 dilution, cytoplasm or membrane; anti-Neu/Her-2 (clone PN2A), 1:100 dilution, membrane. The staining experiments followed the supplier\'s instruction. Negative controls were subjected to the same procedure except that the first antibody was replaced by PBS.

Immunohistochemical staining scores {#s4_3}
-----------------------------------

All slides were evaluated by pathologists without knowledge of patients\' clinical data. The percentage of immunoreactive cells was graded on a scale of 0 to 4: no staining was scored as 0, 1-10% of cells stained scored as 1, 11-50% as 2, 51-80% as 3, and 81-100% as 4. The staining intensities were graded from 0 to 3: 0 was defined as negative, 1 as weak, 2 as moderated, and 3 as strong, respectively. An IHS score of 9-12 was considered as strong immunoreactivity (+++), 5-8 as moderate (++), 1-4 as weak (+), and 0 as negative (−). On the final analysis, the cases with a score of less than 1 were considered as negative, and ≥ 1 was regarded as positive. These criteria were based on our previously published results \[[@R27]\].

Family history evaluation {#s4_4}
-------------------------

Family history of cancer was reviewed from the patient interview record. A positive family history of cancer was defined as a history of cancer within second-degree relatives. First-degree relatives were defined as parents, siblings, or offspring, and second-degree relatives were defined as aunts, uncles, nieces, nephews, or grandparents.

Follow-up {#s4_5}
---------

Follow-up of all patients was carried out according to our hospital\'s standard protocol (every three months for at least 2 years, every six months for the next 3 years, and after 5 years every 12 months for life). The check-up items included physical examination, tumor-marker examination, ultrasound, chest radiography, computed tomographic scan, and endoscopic examination. The median follow-up time was 72 months for all patients.

Statistical analysis {#s4_6}
--------------------

The patients\' features and clinicopathological characteristics were analyzed using the *X*^2^ test for categorical variables. Five-year survival rate was calculated by the Kaplan-Meier method, and the differences between survival curves were examined with the log-rank test. Independent prognostic factors were examined by the multivariate survival analysis using the Cox proportional hazards model. The accepted level of significance was *P* \<0.05. Statistical analyses and graphics were performed using the SPSS 13.0 statistical package (SPSS, Inc., Chicago, IL).
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